[go: up one dir, main page]

BRPI0513405A - tienopirimidinas úteis como inibidores de aurora quinase - Google Patents

tienopirimidinas úteis como inibidores de aurora quinase

Info

Publication number
BRPI0513405A
BRPI0513405A BRPI0513405-6A BRPI0513405A BRPI0513405A BR PI0513405 A BRPI0513405 A BR PI0513405A BR PI0513405 A BRPI0513405 A BR PI0513405A BR PI0513405 A BRPI0513405 A BR PI0513405A
Authority
BR
Brazil
Prior art keywords
useful
thienopyrimidines
kinase inhibitors
aurora kinase
aurora
Prior art date
Application number
BRPI0513405-6A
Other languages
English (en)
Inventor
Willard Lew
Subramanian Baskaran
Johan D Oslob
Josh Yoburn
Min Zhong
Original Assignee
Sunesis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunesis Pharmaceuticals Inc filed Critical Sunesis Pharmaceuticals Inc
Publication of BRPI0513405A publication Critical patent/BRPI0513405A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

TIENOPIRIMIDINAS úTEIS COMO INIBIDORES DE AURORA QUINASE A presente invenção fornece compostos que têm a fórmula (I) onde R¬ 1¬, R¬ 2¬, X¬ 1¬, X¬ 2¬, L¬ 1¬ L¬ 2¬, Y e Z são como definido em classes e subclasse nessa, e composições farmacêuticas desses, como descrito de forma geral e em subclasses nessa, cujos compostos são úteis como inibidores de proteína quinase (por exemplo, Aurora), e assim são úteis, por exemplo, para o tratamento de doenças mediadas por Aurora.
BRPI0513405-6A 2004-07-16 2005-07-15 tienopirimidinas úteis como inibidores de aurora quinase BRPI0513405A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58871804P 2004-07-16 2004-07-16
US63256804P 2004-12-01 2004-12-01
PCT/US2005/025340 WO2006036266A1 (en) 2004-07-16 2005-07-15 Thienopyrimidines useful as aurora kinase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0513405A true BRPI0513405A (pt) 2008-05-06

Family

ID=35527256

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513405-6A BRPI0513405A (pt) 2004-07-16 2005-07-15 tienopirimidinas úteis como inibidores de aurora quinase

Country Status (14)

Country Link
US (2) US7601725B2 (pt)
EP (1) EP1768984B1 (pt)
JP (1) JP2008506714A (pt)
KR (1) KR20070057792A (pt)
AT (1) ATE485300T1 (pt)
AU (1) AU2005290226A1 (pt)
BR (1) BRPI0513405A (pt)
CA (1) CA2573999A1 (pt)
DE (1) DE602005024274D1 (pt)
IL (1) IL180722A0 (pt)
MX (1) MX2007000631A (pt)
NZ (1) NZ552751A (pt)
SG (1) SG156650A1 (pt)
WO (1) WO2006036266A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2573538C (en) 2004-07-30 2014-11-25 Methylgene Inc. Inhibitors of vegf receptor and hgf receptor signaling
AU2006343808B2 (en) 2005-05-20 2012-03-29 Mirati Therapeutics, Inc. Inhibitors of VEGF receptor and HGF receptor signaling
CA2608726C (en) 2005-05-20 2013-07-09 Methylgene Inc. Inhibitors of vegf receptor and hgf receptor signaling
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
CA2645583A1 (en) * 2006-03-20 2007-09-27 F. Hoffman-La Roche Ag Methods of inhibiting btk and syk protein kinases
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
CA2694284A1 (en) * 2007-06-29 2009-01-08 Jennifer Cossrow Heterocyclic compounds useful as raf kinase inhibitors
EP2014663A1 (de) * 2007-07-12 2009-01-14 Bayer Schering Pharma AG Thienopyrimidylamine als Modulatoren des EP2-Rezeptors
KR20100137495A (ko) 2008-03-05 2010-12-30 메틸진 인코포레이티드 단백질 티로신 키나아제 활성의 억제제
JP5455380B2 (ja) * 2008-03-12 2014-03-26 公益財団法人相模中央化学研究所 新規なチアゾール誘導体、及びその製造方法
WO2009113637A1 (ja) * 2008-03-12 2009-09-17 東ソー株式会社 新規なチアゾール誘導体、チアゾール誘導体固定化マトリックス、及びそれらの製造方法
JP5498025B2 (ja) * 2008-03-13 2014-05-21 公益財団法人相模中央化学研究所 新規なチアゾール誘導体固定化マトリックス、及びその製造方法
WO2009114856A2 (en) * 2008-03-14 2009-09-17 Sunesis Pharmaceuticals, Inc. Aurora kinase inhibitors
CA2719579C (en) * 2008-03-25 2020-07-21 Sunesis Pharmaceuticals, Inc. Methods of chemotype evolution
AU2009241469B2 (en) 2008-04-30 2015-05-07 National Health Research Institutes Fused bicyclic pyrimidine compounds as Aurora kinase inhibitors
TW201024307A (en) * 2008-09-10 2010-07-01 Kalypsys Inc Aminopyrimidine inhibitors of histamine receptors for the treatment of disease
DK2331530T3 (da) 2008-09-26 2013-11-11 Nat Health Research Institutes Kondenserede multicycliske forbindelser som proteinkinaseinhibitorer
JP5738196B2 (ja) 2008-12-22 2015-06-17 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼ阻害剤および抗ｃｄ２０抗体の併用
US9925193B2 (en) * 2012-11-20 2018-03-27 Proqinase Gmbh Thioether derivatives as protein kinase inhibitors
CN103012428A (zh) 2013-01-08 2013-04-03 中国药科大学 4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途
US10335494B2 (en) 2013-12-06 2019-07-02 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-CD30 antibodies
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2018123058A (ja) * 2015-06-08 2018-08-09 石原産業株式会社 ジフルオロメチレン化合物
US20180207173A1 (en) 2015-07-21 2018-07-26 Millennium Pharmaceuticals, Inc. Administration of aurora kinase inhibitor and chemotherapeutic agents
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1570494A (en) * 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
ZA782648B (en) * 1977-05-23 1979-06-27 Ici Australia Ltd The prevention,control or eradication of infestations of ixodid ticks
JPS61286373A (ja) * 1985-06-14 1986-12-16 Sankyo Co Ltd フエノキシアルキルアミン誘導体、その製法および殺虫殺ダニ剤
JPH0720943B2 (ja) * 1988-08-19 1995-03-08 宇部興産株式会社 アミノピリミジン誘導体、その製法及び殺虫・殺菌剤
US5141941A (en) 1988-11-21 1992-08-25 Ube Industries, Ltd. Aralkylamine derivatives, and fungicides containing the same
JPH0717638B2 (ja) 1989-08-02 1995-03-01 宇部興産株式会社 アミノピリミジン誘導体、その製造方法及び殺虫、殺菌剤
JPH075569B2 (ja) 1989-08-02 1995-01-25 宇部興産株式会社 アラルキルアミン誘導体、その製法及び殺菌、殺虫剤
US5124333A (en) * 1989-08-02 1992-06-23 Ube Industries, Ltd. Aminopyrimidine derivatives and harmful organisms preventive agent
JPH03173872A (ja) 1989-09-14 1991-07-29 Ube Ind Ltd アミノピリミジン誘導体、その製造方法及び殺虫・殺菌剤
EP0424125A3 (en) 1989-10-18 1991-10-09 Ube Industries, Ltd. Aralkylamine derivatives, preparation method thereof and fungicides containing the same
DE4008726A1 (de) 1990-03-19 1991-09-26 Basf Ag Thieno(2,3-d)pyrimidinderivate
AU651337B2 (en) 1990-03-30 1994-07-21 Dowelanco Thienopyrimidine derivatives
JPH04164072A (ja) 1990-10-26 1992-06-09 Ube Ind Ltd オキシピリミジン誘導体、その製法及び有害生物防除剤
JP2762430B2 (ja) 1991-01-18 1998-06-04 宇部興産株式会社 アラルキルアミノピリミジン類の製法
US5227387A (en) 1991-09-03 1993-07-13 Dowelanco Quinoline nematicidal method
DE4131924A1 (de) * 1991-09-25 1993-07-08 Hoechst Ag Substituierte 4-alkoxypyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel
US5187168A (en) * 1991-10-24 1993-02-16 American Home Products Corporation Substituted quinazolines as angiotensin II antagonists
JPH0710712A (ja) 1993-06-25 1995-01-13 Ube Ind Ltd 花卉園芸用殺菌剤
US5679683A (en) * 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
GB9424676D0 (en) 1994-12-07 1995-02-01 Sandoz Ltd Organic compounds
GB9517986D0 (en) * 1995-09-04 1995-11-08 Sandoz Ltd Organic compounds
AR004010A1 (es) * 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
ATE228518T1 (de) * 1996-06-06 2002-12-15 Otsuka Pharma Co Ltd Amid derivate
DE19827611A1 (de) 1997-07-25 1999-01-28 Basf Ag Verwendung von Arylalkylaminoderivaten als Insektizide
JP3937367B2 (ja) 1998-02-05 2007-06-27 株式会社大塚製薬工場 一酸化窒素合成酵素阻害剤
US6187777B1 (en) * 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
EP1087951B9 (en) 1998-06-18 2006-09-13 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
US6407124B1 (en) * 1998-06-18 2002-06-18 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
US6414156B2 (en) * 1998-10-21 2002-07-02 Bristol-Myers Squibb Company Process for preparing azacycloalkanoylaminothiazoles
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
AU3868500A (en) 1999-03-10 2000-09-28 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
AU3514200A (en) * 1999-03-10 2000-09-28 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
CN1348370A (zh) * 1999-04-15 2002-05-08 布里斯托尔-迈尔斯斯奎布公司 环状蛋白酪氨酸激酶抑制剂
GB2350112A (en) 1999-05-17 2000-11-22 Bayer Ag Pharmaceutically active cycloalkyl ketones
GB2350111A (en) 1999-05-17 2000-11-22 Bayer Ag Oligohydroxyl substituted 3-urea-benzofuran and pyridofuran derivatives
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
AU1071301A (en) 1999-11-01 2001-05-14 Eli Lilly And Company Pharmaceutical compounds
US6515004B1 (en) * 1999-12-15 2003-02-04 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
EP1785134A3 (en) 2000-01-19 2009-02-18 Synvista Therapeutics, Inc. Use of thiazole, imidazole and oxazole compounds for the treatment of disorders associated with protein aging
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
US6534531B2 (en) 2000-04-27 2003-03-18 Bristol-Myers Squibb Company Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy
WO2001083456A1 (en) 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Condensed heteroaryl derivatives
JP2002105081A (ja) 2000-07-28 2002-04-10 Nikken Chem Co Ltd 新規チオフェンニ環化合物
US6627767B2 (en) * 2000-08-29 2003-09-30 Abbott Laboratories Amino(oxo) acetic acid protein tyrosine phosphatase inhibitors
WO2002018321A2 (en) 2000-08-29 2002-03-07 Abbott Laboratories Amino(oxo)acetic acid protein tyrosine phosphatase inhibitors
IT1318696B1 (it) * 2000-09-15 2003-08-27 Pharmacia & Upjohn Spa Coniugati di glutatione con derivati della distamicina ad attivita'antitumorale.
US6503914B1 (en) * 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
DK1347971T3 (da) * 2000-12-21 2006-05-15 Bristol Myers Squibb Co Thiazolylinhibitorer af tyrosinkinaser fra Tec-familien
JPWO2002051849A1 (ja) * 2000-12-26 2004-04-22 第一製薬株式会社 Ｃｄｋ４活性阻害剤
EP1353676A4 (en) * 2000-12-29 2006-05-31 Alteon Inc METHOD FOR THE TREATMENT OF FIBROUS OR OTHER INDICATIONS
DE60130030T2 (de) 2000-12-29 2008-04-30 Alteon Inc. Verfahren zur behandlung von glaukom
WO2002053156A1 (en) 2000-12-29 2002-07-11 Alteon, Inc. Method for treating glaucoma ii b
US6693125B2 (en) 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
ATE509014T1 (de) 2001-01-26 2011-05-15 Chugai Pharmaceutical Co Ltd Malonyl coa-decarboxylase inhibitoren als stoffwechselmodulatoren
US6660737B2 (en) * 2001-05-04 2003-12-09 The Procter & Gamble Company Medicinal uses of hydrazones
US20040235867A1 (en) 2001-07-24 2004-11-25 Bilodeau Mark T. Tyrosine kinase inhibitors
CA2469340A1 (en) 2001-12-06 2003-06-19 Gtx Inc. Treating muscle wasting with selective androgen receptor modulators
US20050009845A1 (en) * 2001-12-19 2005-01-13 Caferro Thomas R. Thienopyrimidine compounds as protein tyrosine kinase inhibitors
WO2003055890A1 (en) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
SI1463506T1 (sl) * 2001-12-24 2010-01-29 Astrazeneca Ab Substituirani kinazolinski derivati kot inhibitorji kinaz Aurora
WO2003064428A1 (en) 2002-01-29 2003-08-07 H. Lundbeck A/S Furano- and thienopyrimidines as neurokinase inhibitors
KR20100112659A (ko) 2002-02-07 2010-10-19 지티엑스, 인코포레이티드 선택적 안드로겐 수용체 조절자를 이용한 양성 전립선 과형성증의 치료 방법
AU2003228614A1 (en) 2002-04-23 2003-11-10 Chugai Seiyaku Kabushiki Kaisha Lxr modulators
WO2004002481A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
AU2003251904A1 (en) 2002-07-15 2004-02-02 Combinatorx, Incorporated Combinations of drugs for the treatment of neoplasms
AR044743A1 (es) 2002-09-26 2005-10-05 Nihon Nohyaku Co Ltd Herbicida, metodo de emplearlo, derivados de tienopirimidina sustituida,compuestos intermediarios, y procedimientos que se utilizan para producirlos,
EP1558232A4 (en) 2002-10-15 2008-07-02 Gtx Inc TREATMENT OF FAT SUPPORT WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS
US20040197928A1 (en) 2002-10-15 2004-10-07 Dalton James T. Method for detecting selective androgen receptor modulators
CA2501874A1 (en) 2002-10-16 2004-04-29 Gtx, Inc. Treating androgen decline in aging male (adam)-associated conditions with sarms
US20040171075A1 (en) 2002-12-31 2004-09-02 Flynn Daniel L Modulation of protein functionalities
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
CN102584813B (zh) 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途

Also Published As

Publication number Publication date
US20100179123A1 (en) 2010-07-15
AU2005290226A1 (en) 2006-04-06
MX2007000631A (es) 2007-03-30
SG156650A1 (en) 2009-11-26
EP1768984B1 (en) 2010-10-20
DE602005024274D1 (de) 2010-12-02
US7601725B2 (en) 2009-10-13
EP1768984A1 (en) 2007-04-04
KR20070057792A (ko) 2007-06-07
US20060035908A1 (en) 2006-02-16
ATE485300T1 (de) 2010-11-15
JP2008506714A (ja) 2008-03-06
NZ552751A (en) 2010-11-26
CA2573999A1 (en) 2006-04-06
WO2006036266A1 (en) 2006-04-06
IL180722A0 (en) 2007-06-03

Similar Documents

Publication Publication Date Title
BRPI0513405A (pt) tienopirimidinas úteis como inibidores de aurora quinase
EA200700189A1 (ru) Производные хиназолина в качестве ингибиторов parp
SE0302811D0 (sv) Novel compounds
MY169515A (en) Quinazolinedione derivatives as parp inhibitors
ATE433447T1 (de) Pyrimiidinverbindungen
TW200610531A (en) Phthalazine derivatives as PARP inhibitors
CY1110900T1 (el) Χημικες ενωσεις
CY1108275T1 (el) Χημικες ενωσεις
UA91002C2 (ru) 7-фенилалкилзамещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поле(адф-рибоза)полимеразы
SE0301700D0 (sv) Novel compounds
TW200801003A (en) Novel compounds
ATE384061T1 (de) Imidazo- und thiazolopyridine als jak3-kinase- inhibitoren
EA201070247A1 (ru) Ингибиторы протеасом
SE0101675D0 (sv) Novel composition
TW200716606A (en) Chemical compounds
TW200800963A (en) Chemical compounds
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
ATE419253T1 (de) Inhibitoren von thienopyridin- und furopyridinkinase
EA200800546A1 (ru) Бензимидазолтиофеновые соединения в качестве ингибиторов polo-подобных киназ (plk)
TW200738659A (en) Novel compounds
SE0403086D0 (sv) Compounds
EA200800393A1 (ru) Новые соединения-аналоги камптотецина, способ их получения и фармацевтические композиции, которые их содержат
MX2008007195A (es) Inhibidores de proteasas de cisteina, composiciones farmaceuticas de las mismas y sus aplicaciones terapeuticas.
ATE540951T1 (de) Substituierte 7,8-dihydro-1h-pyrimidoä4,5- büdiazepin-4-amine als kinase inhibitoren

Legal Events

Date Code Title Description
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 7A E 8A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2256 DE 01/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A, 8A, 9A, 10A, 11A, 12A, 13A, 14A E 15A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.